Ask AI
ctDNA Monitoring and Tx in HRpos HER2neg MBC

CE / CME

FAQs: Current Utility of ctDNA Monitoring and Treatment Selection for Patients With ESR1-Mutant and/or PI3K Pathway Altered HR-positive/HER2-negative MBC

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Pharmacists: 0.25 contact hour (0.025 CEUs)

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: July 17, 2025

Expiration: January 16, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following most accurately describes the schedule for ctDNA analysis of emergent ESR1 mutations in the multistep, phase III SERENA-6 trial that evaluated a switch to camizestrant plus a CDK4/6 inhibitor vs continuation of first-line therapy with an aromatase inhibitor plus a CDK4/6 inhibitor among patients with HR-positive, HER2-negative advanced breast cancer?